Business Context and Reporting Period
Company: electroCore, Inc. (ECOR)
Filing Type: Form 8-K (Current Report)
Date of Report: February 16, 2021
Reporting Period: Single event date (February 16, 2021)
This filing reports a regulatory milestone for the company's gammaCoreTM non-invasive vagus nerve stimulation device.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report regarding a specific event and does not contain financial statements or performance metrics.
Material Changes
Regulatory Clearance: On February 16, 2021, the U.S. Food and Drug Administration (FDA) cleared gammaCoreTM under Section 510(k) of the Federal Food, Drug, and Cosmetic Act for a new indication.
- Indication: Treatment of migraine in adolescents between 12 and 17 years of age.
- Significance: Expands the approved patient demographic for the company's primary product.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the FDA clearance but does not include forward-looking guidance, financial outlook, or specific risk factors within the text of this report.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on commercialization plans for the adolescent indication.
- Confirm the specific limitations or conditions of the FDA 510(k) clearance for the 12-17 age group.
- Review subsequent quarterly reports (10-Q/10-K) to assess the financial impact of this expanded indication on revenue growth.